Written by the Dynamo Delay Team · Last Updated: February 2026
Key Takeaway: The delay spray market is evolving fast. Nanotechnology-based delivery systems, combination formulations, and precision dosing are moving through development pipelines. Meanwhile, telehealth is making PE treatment more accessible than ever. A look at what's arriving and what's already available.
Delay sprays have worked the same basic way for decades: apply a topical anesthetic, wait, and go. The active ingredients haven't changed much since lidocaine entered clinical use in 1948. But the technology around those ingredients, how they're delivered, dosed, and combined, is advancing rapidly.
If you're already using a product that works for you, nothing here means you should wait around for something better. Today's formulations are clinically effective and well-tested. But if you're curious about where PE treatment is headed, this is the landscape.
Drug Delivery: The Biggest Area of Innovation
The active ingredients work. The frontier is getting them to the right nerve fibers faster, more consistently, and with less residue.
Nanotechnology and Liposomal Delivery
Researchers are exploring nanoparticle encapsulation, wrapping lidocaine molecules in tiny lipid bubbles (liposomes) that can penetrate skin more efficiently and release the drug at controlled rates. The potential benefit: faster onset with lower total drug volume, meaning less surface residue and virtually zero partner transfer risk.
Liposomal lidocaine is already used in pain management. Products like LMX 4 rely on this technology. Adapting it for PE products is an engineering challenge, not a scientific one. Expect to see the first nanodelivery PE products within the next 3-5 years.
Metered-Dose Precision
Current metered-dose sprays deliver a fixed amount per pump, typically 7.5-10 mg of lidocaine. Next-generation designs could offer adjustable dosing. Imagine a dial-a-dose spray where you set your preferred level from 1 to 5. Some prototypes in development use microelectronic valves to control spray volume with high precision.
The difference between optimal and excessive desensitization can be a single spray. More granular control means a more consistent experience. For now, understanding how current sprays work and dialing in your dose with a 2-3 session calibration is the best approach.
New Formulation Approaches
Combination Topicals
The EU-approved Fortacin spray (PSD502) combines lidocaine with prilocaine, two anesthetics that target different sodium channel subtypes. This dual-action approach produced the strongest clinical trial results to date: a 6.3x increase in IELT, per Dinsmore and Wyllie's 2009 study. While Fortacin remains prescription-only in Europe and isn't available in the US, it demonstrates the principle that combination formulations can outperform single-ingredient products.
Future OTC products may explore combining low-dose anesthetics with other active compounds, such as vasodilators that improve blood flow or mild serotonergic agents that support the brain's ejaculatory inhibition pathway. These combinations are in early research stages.
Transdermal Patches and Wearables
Concept-stage products include adhesive patches applied to the penile shaft that deliver continuous low-dose anesthetic over hours. The goal is maintaining a baseline level of desensitization throughout a sexual encounter without reapplication. Microneedle patch technology, already used in vaccine delivery, could make this practical by enhancing skin penetration without the "wet" application of sprays.
Topical SSRIs
Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed oral medication for PE, but they come with systemic side effects: nausea, fatigue, reduced libido. Researchers are investigating topical SSRI formulations that could modulate serotonin signaling locally at the penile nerve level without systemic exposure. This is still in preclinical stages, but the concept is promising for men who want a non-numbing approach.
The Regulatory Landscape
The US is notably behind Europe in having a dedicated, approved prescription product for PE. Fortacin (lidocaine-prilocaine spray) was approved by the European Medicines Agency in 2013 but has never received FDA approval for the US market.
Why? The FDA requires specific PE indication trials with endpoint definitions that differ slightly from EMA standards. Several companies have explored the US approval pathway, but the economics are challenging. The OTC market already serves most consumers, making a prescription-only product a tough business case.
For consumers: the best OTC products (like Dynamo Delay at 13% lidocaine) already use the same active ingredients at effective concentrations. A prescription version would likely offer marginal improvement over what's currently available.
Telehealth Is Changing Access
The biggest near-term shift isn't in the spray itself. It's in how men access PE treatment.
Telehealth platforms like Hims, Ro, and others now offer PE consultations, prescription dapoxetine (where available), and delay spray bundles shipped directly to your door. The stigma barrier, having to walk into a pharmacy or sit in a doctor's waiting room, is dissolving.
For many men, the real innovation isn't a better molecule. It's the ability to get help without the embarrassment. The PEPA survey (Porst et al., 2007) found only 9% of men with PE had ever sought medical help, primarily because of stigma. Telehealth is directly attacking that 91% gap.
What About Non-Spray PE Treatments?
Delay sprays are one tool. The broader PE treatment landscape includes several active research areas:
-
On-demand dapoxetine is an SSRI designed specifically for PE, approved in 60+ countries but not in the US. Taken 1-3 hours before sex, it increases IELT by 2.5-3x in clinical trials.
- SS-cream is a Korean herbal topical cream containing nine plant extracts. Choi et al. published a study in Urology (2000) showing it increased IELT from 1.37 to 10.9 minutes. It's available in South Korea but not widely available elsewhere.
-
Neuromodulation devices are emerging wearables that use gentle electrical stimulation to the perineum or dorsal penile nerve to modulate ejaculatory signaling. Very early stage but conceptually interesting.
- Gene therapy research into serotonin transporter gene modulation is extremely early. Decades away from clinical use, if ever. Still, it represents the ultimate "fix the root cause" approach.
What Should You Do Right Now?
Don't wait for future products when today's options work. Clinical evidence for lidocaine-based delay sprays is strong and well-established. Current top-rated sprays deliver real, measurable improvements in ejaculatory control, often on the first use.
The best strategy is layering: use a delay spray for immediate results while building long-term control through pelvic floor exercises and behavioral techniques. When next-gen products arrive, you'll be starting from a stronger baseline.
Frequently Asked Questions
Will there be a prescription delay spray in the US?
Possibly, but it's not imminent. Fortacin (lidocaine-prilocaine) is approved in Europe but hasn't pursued FDA approval for the US market. The OTC market already provides effective products at clinical concentrations, making the business case for a prescription version challenging. Current OTC options like Dynamo Delay (13% lidocaine) use the same active ingredients at effective doses.
Are nanotechnology delay sprays available yet?
Not specifically for PE, but liposomal lidocaine technology already exists in pain management products. Adapting this technology for delay sprays could improve onset time, reduce residue, and minimize partner transfer. Expect to see the first nanodelivery PE products within 3–5 years.
What new PE treatments are in clinical trials?
Active research areas include topical SSRI formulations (targeting serotonin locally without systemic side effects), combination topical agents (lidocaine + vasodilators), and neuromodulation devices that use electrical stimulation to modulate ejaculatory signaling. Most are in early-stage research.
Will delay sprays get better over time?
Yes — primarily in delivery technology rather than active ingredients. Expect faster onset, more precise dosing controls, reduced residue, and near-zero partner transfer. The active ingredient (lidocaine) has been optimized over 80 years and is unlikely to be replaced, but how it reaches the nerve endings will improve significantly.
Is telehealth a good option for PE treatment?
Absolutely. Telehealth removes the stigma barrier that prevents most men from seeking help. Platforms offer virtual consultations, prescription options, and discreet delivery. For men who haven't tried OTC delay sprays yet, they're available without a prescription — but telehealth is ideal for exploring additional treatments like dapoxetine or combination therapy.
Sources
- Dinsmore WW, Wyllie MG. "PSD502 Improves Ejaculatory Latency, Control and Sexual Satisfaction." BJU International. 2009;103(7):940-949.
- Porst H, Montorsi F, Rosen RC, et al. "The PEPA Survey." European Urology. 2007;51(3):816-824.
- Choi HK, Jung GW, Moon KH, et al. "Clinical Study of SS-Cream in Patients with Lifelong Premature Ejaculation." Urology. 2000;55(2):257-261.
- McMahon CG, et al. "Efficacy and Safety of Dapoxetine for PE." Journal of Sexual Medicine. 2011;8(2):524-539.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personalized guidance.
